Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian F Schoppmann

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Anticancer Research|July 31, 2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tractAysegül Ilhan-Mutlu, Matthias Preusser, Sebastian F Schoppmann, et al.
European Radiology|June 29, 2011
Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological resultsAhmed Ba-Ssalamah, Wolfgang Matzek, Susanne Baroud, et al.
Anticancer Research|March 14, 2013
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapiesMatthias Preusser, Anna S Berghoff, Aysegül Ilhan-Mutlu, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 20, 2014
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group studyDaniela Kandioler, Sebastian F Schoppmann, Ronald Zwrtek, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2021
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatmentGerd Jomrich, Dagmar Kollmann, Dariga Ramazanova, et al.
Annals of the New York Academy of Sciences|October 15, 2013
Upper esophageal sphincter dysfunction: diverticula-globus pharyngeusAntonio Schindler, Francesco Mozzanica, Enrico Alfonsi, et al.
Surgical Endoscopy|August 20, 2014
Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trialJohannes Zacherl, Aviel Roy-Shapira, Luigi Bonavina, et al.
Journal of Cancer Research and Clinical Oncology|September 26, 2023
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinomaHannah C Puhr, Clemens C Weirauch, Flora Selimi, et al.
European Surgery : ACA : Acta Chirurgica Austriaca|December 6, 2021
Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapyGerd Jomrich, Dagmar Kollmann, Lavinia Wilfing, et al.
Annals of the New York Academy of Sciences|February 6, 2026
Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?Dagmar Kollmann, Cansel Etyemez, Reza Asari, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Anticancer Research|July 31, 2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tractAysegül Ilhan-Mutlu, Matthias Preusser, Sebastian F Schoppmann, et al.
European Radiology|June 29, 2011
Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological resultsAhmed Ba-Ssalamah, Wolfgang Matzek, Susanne Baroud, et al.
Anticancer Research|March 14, 2013
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapiesMatthias Preusser, Anna S Berghoff, Aysegül Ilhan-Mutlu, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 20, 2014
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group studyDaniela Kandioler, Sebastian F Schoppmann, Ronald Zwrtek, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2021
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatmentGerd Jomrich, Dagmar Kollmann, Dariga Ramazanova, et al.
Annals of the New York Academy of Sciences|October 15, 2013
Upper esophageal sphincter dysfunction: diverticula-globus pharyngeusAntonio Schindler, Francesco Mozzanica, Enrico Alfonsi, et al.
Surgical Endoscopy|August 20, 2014
Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trialJohannes Zacherl, Aviel Roy-Shapira, Luigi Bonavina, et al.
Journal of Cancer Research and Clinical Oncology|September 26, 2023
Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinomaHannah C Puhr, Clemens C Weirauch, Flora Selimi, et al.
European Surgery : ACA : Acta Chirurgica Austriaca|December 6, 2021
Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapyGerd Jomrich, Dagmar Kollmann, Lavinia Wilfing, et al.
Annals of the New York Academy of Sciences|February 6, 2026
Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?Dagmar Kollmann, Cansel Etyemez, Reza Asari, et al.
Pageof 15